Human VEGFR2 shRNA Stable Transfected GFP-HUVECs
Quick Actions
Documentation 0 files
Product Overview
Description
Human VEGFR2 shRNA Stable Transfected GFP-HUVECs are genetically modified Human Umbilical Vein Endothelial Cells (HUVECs) that stably express a short hairpin RNA (shRNA) targeting VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) while simultaneously expressing Green Fluorescent Protein (GFP).
The stable knockdown of VEGFR2 suppresses VEGF-mediated signaling pathways involved in endothelial cell proliferation, migration, survival, and angiogenesis. GFP expression enables convenient visualization, tracking, and quantification of cells in vitro and in vivo.
Guarantee expansion for a minimum of 2-5 population
doublings.
IMPORTANT: Quality warranty requires use of NeoBioPharma media. Biohazardous material despite negative pathogen testing. Quality claims must be reported within 1 month.
Key Features
Catalog Number: NBP-0001-siRNAVR2GFP
Product Format: Frozen
Vial Cell Number: > 5x10[5] cells/vial
Passage:1(P1)
Storage: Liquid Nitrogen, Vapor Phase
Intended Use: Research use only (RUO)
CELL CHARACTERISTICS
-Stable shRNA-mediated silencing of VEGFR2 expression.
-Constitutive GFP expression for fluorescence-based monitoring.
-Reduced responsiveness to VEGF stimulation.
-Decreased endothelial proliferation and migration.
-Impaired tube formation and angiogenic activity.
-Typical endothelial cobblestone morphology under standard culture conditions.
-Positive for endothelial markers including:
-CD31 (PECAM-1)
-VE-Cadherin (CD144)
-von Willebrand Factor (vWF)
-eNOS
-Suitable for long-term studies due to stable transgene integration.
-High transduction efficiency and reproducible gene knockdown.
Quick Facts
Product Type
Human Endothelial cells
Viability
>95% viable (Trypan Blue exclusion)
Applications
-Angiogenesis Research Investigation of VEGFR2-d…
Availability
In Stock • Global Shipping
Technical Specifications
Primary Applications
Applications & Use Cases
Primary Applications
-Angiogenesis Research Investigation of VEGFR2-dependent angiogenic mechanisms. Evaluation of endothelial sprouting and capillary network formation. Analysis of VEGF signaling pathways. -Cancer Research Tumor angiogenesis studies. Assessment of anti-angiogenic therapeutics. Investigation of endothelial-tumor cell interactions. -Drug Discovery and Screening Screening of VEGFR inhibitors and anti-vascular compounds. Evaluation of novel biologics targeting VEGF/VEGFR pathways. High-content fluorescence-based drug screening.
Suitable for -angiogenesis research investigation of vegfr2-dependent angiogenic mechanisms. evaluation of endothelial sprouting and capillary network formation. analysis of vegf signaling pathways. -cancer research tumor angiogenesis studies. assessment of anti-angiogenic therapeutics. investigation of endothelial-tumor cell interactions. -drug discovery and screening screening of vegfr inhibitors and anti-vascular compounds. evaluation of novel biologics targeting vegf/vegfr pathways. high-content fluorescence-based drug screening. studies and research applications
Research Areas
In Vitro Studies
Cell culture and screening applications
Molecular Biology
Gene expression & signaling studies
Drug Discovery
Screening & validation studies
Disease Modeling
Pathophysiology research
Support & Resources
Technical Support
Our experts are available for technical questions and protocol assistance.
Contact Support
